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Human SULT1A1 is primarily responsible for sulfon-
ation of xenobiotics, including the activation of pro-
mutagens, and it has been implicated in several forms of
cancer. Human SULT1A3 has been shown to be the ma-
jor sulfotransferase that sulfonates dopamine. These
two enzymes shares 93% amino acid sequence identity
and have distinct but overlapping substrate prefer-
ences. The resolution of the crystal structures of these
two enzymes has enabled us to elucidate the mecha-
nisms controlling their substrate preferences and inhi-
bition. The presence of two p-nitrophenol (pNP) mole-
cules in the crystal structure of SULT1A1 was
postulated to explain cooperativity at low and inhibi-
tion at high substrate concentrations, respectively. In
SULT1A1, substrate inhibition occurs with pNP as the
substrate but not with dopamine. For SULT1A3, sub-
strate inhibition is found for dopamine but not with
pNP. We investigated how substrate inhibition occurs in
these two enzymes using molecular modeling, site-di-
rected mutagenesis, and kinetic analysis. The results
show that residue Phe-247 of SULT1A1, which interacts
with both p-nitrophenol molecules in the active site, is
important for substrate inhibition. Mutation of pheny-
lalanine to leucine at this position in SULT1A1 results in
substrate inhibition by dopamine. We also propose,
based on modeling and kinetic studies, that substrate
inhibition by dopamine in SULT1A3 is caused by bind-
ing of two dopamine molecules in the active site.
The cytosolic sulfotransferase (SULT)1 gene superfamily en-
codes enzymes catalyzing sulfonation of numerous xeno- and
endobiotics, such as drugs, hormones (e.g. 17-estradiol, thy-
roid hormones, and dehydroepiandrosterone), chemical carcin-
ogens, bile acids, and neurotransmitters. These substrates may
undergo sulfonation directly as in phase II metabolism (e.g.
minoxidil, paracetamol) or following phase I metabolism after
introduction of a functional hydroxyl group (e.g. N-hydroxyl
arylamines). The sulfonate donor for these reactions is 3-
phosphoadenosine 5-phosphosulfate (PAPS; Refs. 1–3). Sul-
fonation is generally considered to be a detoxification pathway
for a broad range of compounds, because conjugation with a
sulfonate (SO3
1) renders substrates more hydrophilic and fa-
cilitates their excretion. However, evidence has emerged in
recent years that this reaction can lead to formation of highly
reactive intermediates (e.g. with N-hydroxy heterocyclic and
aromatic arylamines) that can bind to DNA resulting in muta-
genicity and carcinogenicity (4–6). Therefore, various studies
have investigated its role in human cancer and in particular
polymorphisms in SULT1A1 have been implicated in the pre-
disposition to lung cancer (7), age of onset in breast cancer (8),
and increased risk of breast cancer (9, 10).
Fifty-six cytosolic SULT cDNAs have been cloned and char-
acterized from bacteria to human (11–13). SULT1, SULT2,
SULT3, SULT4, and SULT5 gene families have been identified
in mammals. Of these, only SULT1, SULT2, and SULT4 have
been identified in humans. These include seven members of the
SULT1 family (SULT1A1, SULT1A2, SULT1A3, SULT1B1,
SULT1C1, SULT1C2, and SULT1E1), two members of the
SULT2 family (SULT2A1 and SULT2B), and one member of
the SULT4 family (SULT4A1). Although each SULT has dis-
tinct substrate preferences, the range of molecules accepted
can be broad and may be overlapping. In general, the SULT1
family catalyzes sulfonation of small phenols, monoamine neu-
rotransmitters (e.g. dopamine), thyroid hormones, and estro-
gens, and the SULT2 family sulfonates steroid hormones. To
date, neither an endogenous nor an exogenous substrate has
been found for SULT4 A1.
Although there has been an increase in structure function
studies as a result of an expansion of SULT x-ray crystal
structures published, substrate binding and inhibition mech-
anisms are still far from clear. The crystal structures of
mouse estrogen SULT1E1 (14), human SULT1A3 (15, 16),
SULT domain of the human membrane bound heparan sulfate
N-deacetylase/N-sulfotransferase 1 (17), human hydroxy-
steroid SULT2A1 (18, 19), and human estrogen SULT1E1 (20);
in addition, site-directed mutagenesis of critical amino acids in
these enzymes has provided information on catalytic mecha-
nism of these enzymes. Recently, this laboratory also reported
the structure of human SULT1A1, crystallized in the presence
of 3-phosphoadenosine 5-phosphate (PAP) with two p-nitro-
phenol (pNP) molecules bound in the active site (21). This
structure is similar to the other SULT enzymes as it incorpo-
rates a core PAP binding site. However, it was the first struc-
ture to show two molecules of the substrate bound in the active
site.
Substrate inhibition is characteristic of many SULT en-
zymes and has been reported previously with human SULTA1
and SULT1A3 with pNP and dopamine, respectively (22–24).
The presence of two substrate molecules in the SULT1A1 struc-
ture was postulated to explain the slight cooperativity observed
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at low concentrations of substrate and the inhibition observed
at higher concentrations of pNP. In previous work (21), we
proposed that inhibition is caused by impeded catalysis when
both binding sites are occupied. In SULT1A1, substrate inhi-
bition is evident when the pNP is used as the acceptor molecule
but not when dopamine is the substrate. To investigate this
further, we modeled dopamine into the substrate-binding
pocket of SULT1A1 to show that two dopamine molecules could
fit. Dopamine is the preferred substrate of SULT1A3 and our
initial resolution of SULT1A3 structure showed large stretches
of disorder that account for about 25% of its structure, which
may in part be caused by lack of substrate binding (15). There-
fore, we have also modeled the substrate-binding pocket of
SULT1A3 to investigate dopamine binding and to determine
how substrate inhibition takes place in this enzyme. Finally,
site-directed mutagenesis was performed on residues interact-
ing with the substrate molecule at the active site of SULT1A1
indicated that the flexible residue Phe-247 is important for
substrate inhibition by dopamine.
MATERIALS AND METHODS
SULT1A1 and SULT1A3 were previously subcloned into the pET
28a() vector (Novagen, Victoria, Australia). The substrates dopamine,
pNP, and PAPS were purchased from Sigma. [35S]PAPS was purchased
from Amrad Pharmacia Biotechnology (Victoria, Australia). The prim-
ers for sequencing and site-directed mutagenesis were obtained from
PROLIGO (New South Wales, Australia). The PCR kit Pfu-Turbo was
obtained from Stratagene. The restriction enzyme DpnI was purchased
from New England Biolabs. All other reagents were of molecular biology
or analytical grade.
Site-Directed Mutagenesis—Double-stranded primers encoding a sin-
gle amino acid mutation in the SULT1A1 gene were used to obtain
SULT1A1 mutants. Twenty cycles of PCR were carried out with dena-
turation at 94 °C for 30 s, annealing at 55 °C for 1 min, and extension
at 68 °C for 12 min. The reaction contained 50 ng of DNA template,
primers, 200 M concentrations of each of the four deoxynucleotide
triphosphates (dNTPs), 1 PfuTurbo buffer, and 2.5 units of PfuTurbo
DNA polymerase. The PCR product was treated with DpnI for 1 h at
37 °C followed by transformation of BL21 (DE3) Escherichia coli cells.
The transformed bacteria were used to amplify the plasmid for sequenc-
ing as well as for protein expression of the SULT1A1 mutants. The
mutated cDNA sequences were confirmed by automated sequencing
carried out by the Australian Genome Research Facility (Brisbane,
Australia) with the ABI Prism dye terminator cycle sequencing ready
reactions (PerkinElmer Life Sciences) using the T7-promoter and ter-
minator universal primers.
Expression, Purification, and Enzyme Activity—Expression of the
recombinant proteins was performed as described previously (15, 25,
26). The protein was purified utilizing the hexahistadine tag on the N
terminus of the SULT1A1 and SULT1A3 cDNAs by TALON cobalt
affinity (Clontech Laboratories) chromatography. Protein purity was
estimated by SDS-polyacrylamide gel electrophoresis and only fractions
with the highest purity were used for enzyme assay. The purified
protein was mixed with glycerol to a final concentration of 20% (v/v) and
stored at 70 °C before use. Protein concentration was determined by
the BCA method (Sigma).
Enzyme activity assays were performed using the method described
by Foldes and Meek (27) as modified by Brix et al. (26). The reaction
mixture consisted of 20 M [35S]PAPS, 0.1 g/ml SULT1A1, 10 mM
potassium phosphate buffer, pH 7.0, and varying concentrations of the
substrates in a final volume of 500 l. Reactions were started by adding
the enzyme to the reaction mixture and then incubated for 20 min at
37 °C. The reaction was terminated by adding 0.1 M barium hydroxide,
0.1 M barium acetate, and 0.1 M zinc sulfate, precipitating the enzyme
and unreacted [35S]PAPS. Assays were performed in duplicate and the
radioactivity of the sulfonated product was determined using a liquid
scintillation counter (Tri-Carb 2500; PerkinElmer Life and Analytical
Sciences). The incubation time and protein concentration used were
chosen to be within the linear range for product formation.
Kinetic Data Analysis—Kinetic experiments were analyzed by non-
linear regression, fitting the appropriate equation to the data. This
regression analysis was performed using the Grafit program, version 5
(Erithacus Software Limited, Surrey, UK).
Molecular Modeling—Modeling of substrates into the human
SULT1A1/SULT1A3 substrate-binding pocket was performed using the
docking program GOLD (Cambridge University) with 10 genetic algo-
rithm runs and default parameters (28). The structure of SULT1A3 was
modeled using the crystal structure of human SULT1A1 (Protein Data
Bank code 1LS6) and minimized in Crystallography and NMR System
software (29). The quality of the model was assessed with Procheck (30).
RESULTS
Molecular Modeling—Previously we proposed a kinetic
model for SULT1A1 that explains slight cooperativity at very
low substrate concentrations and inhibition at high substrate
concentrations of pNP (21). When pNP is utilized as the accep-
tor molecule for SULT1A1, substrate inhibition is observed
above 2 M (Fig. 1a). However, when dopamine is used as the
acceptor molecule, no obvious substrate inhibition is seen (Fig.
1b). The reverse is found for SULT1A3 (Fig. 1, c and d), where
the preferred substrate dopamine exhibits substrate inhibition
above 9 M, whereas pNP follows Michaelis-Menten kinetics.
The analysis of the crystal structure of SULT1A1 shows that
two pNP molecules can be accommodated in the substrate-
binding pocket (Fig. 2a). To investigate why there is no sub-
strate inhibition of SULT1A1 by dopamine, we modeled this
substrate into the active site of SULT1A1 (Fig. 2b).
Our model of SULT1A1 with dopamine showed that the
substrate-binding pocket could accommodate two molecules of
dopamine, although some “clashes” were observed with a resi-
due that seemed to have some flexibility (Phe-247) when posi-
tioning the second dopamine molecule. With a small shift in
orientation, either the 3-OH or 4-OH of dopamine could be
oriented for sulfonation. Because 3-O sulfonated dopamine is
reported to be high in humans (16), the dopamine was orien-
tated for sulfonation at the 3-O position. In this orientation, it
seems to form close contacts with the flexible Phe-247 and
Val-148. By rotating Phe-247 to an alternate conformation (Fig.
2b), the two dopamine molecules could fit within the substrate-
binding pocket. To determine whether the smaller leucine res-
idue, found at this position in human SULT1A3, facilitates the
binding of second dopamine molecule, we modeled the sub-
strate-binding pocket of SULT1A3 using the SULT1A1 struc-
ture and investigated the positioning of two dopamine mole-
cules in the substrate-binding pocket.
A computer model of SULT1A3 was constructed using the
coordinates of SULT1A1 obtained from the Protein Data Bank
(code 1LS6). Both enzymes have 295 residues, and 21 residues
differ between these two enzymes. In the SULT1A1 structure,
these residues were mutated to the corresponding SULT1A3
residues, the model was energy minimized in Crystallography
and NMR System software, and the validity of the model was
assessed. The backbone residues in the SULT1A3 model can be
superimposed on the SULT1A1 crystal structure (295 C at-
oms with root-mean-square deviation 1.6 Å). PAPS was mod-
eled into SULT1A3 based on the SULT1E1-PAPS structure
(Protein Data Bank code 1HY3; Ref. 20) and dopamine was
docked using the GOLD program with default parameters. The
model of SULT1A3 (Fig. 2c) with dopamine showed that two
molecules of substrate are easily accommodated in the sub-
strate-binding pocket; positioning of the second dopamine mol-
ecule was easier with a leucine residue at position 247.
Kinetic Analysis—Previously, we analyzed the substrate sat-
uration and substrate inhibition kinetics of SULT1A1 toward
pNP using an equation (Equation 1) derived from the observa-
tion that the enzyme structure contains two bound substrate
molecules (21).
v  VSK1  S	/K2K3  SK3  S2	 (Eq. 1)
The difficulty with this equation is that it contains three
kinetic constants (K1, K2, and K3) that have no obvious physical
meaning. Only V, the rate as [S] 3 , relates directly to an
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observable quantity. We realized that this equation may be
rewritten in terms of more normal constants,
v  VmS VS2/Ki	/Km  S S2/Ki	 (Eq. 2)
where Vm and Km are the conventional maximum velocity and
Michaelis constant, respectively, that would be observed if
there were no substrate inhibition, whereas Ki is the substrate
concentration that would give a rate midway between Vm and
V, if Km was very small. Although this equation fits the data
very well, the nonlinear regression analysis showed that there
are extremely high parameter correlations between the pairs
Vm and Km, Vm and Ki, and Km and Ki. This means that
estimates of each of the parameters are unreliable because the
values are highly dependent upon one another.
Further investigation showed that an empirical simplifica-
tion could eliminate one parameter and these undesirable cor-
relations, while maintaining a good fit. The revised equation is
as follows.
v  ksS VS2/Ks2	/1 S2/Ks2	 (Eq. 3)
The parameter ks is the specificity constant, which corresponds
to the ratio Vm/Km for an enzyme that exhibits Michaelis-
Menten kinetics. Graphically, it is the slope of the tangent to
the activity versus [substrate] curve at the origin. The specific-
ity constant can be used to directly compare the efficiencies of
different enzymes (or mutants) for any given substrate, or
different substrates with any given enzyme. V has the same
definition as in Equations 1 and 2. The third parameter, Ks, is
a “substrate constant” with no exact physical meaning but that
acts as a scaling factor for the substrate concentration axis. It
can be used as an intermediate vehicle to calculate the more
meaningful parameters Sp (the concentration of substrate that
results in the peak rate) or Vp (the rate at [S] 
 Sp) using the
relationships below.
Sp  Ks2  2V/ks	1/2 (Eq. 4)
Vp  ksSp/2 (Eq. 5)
Although it would be desirable to use Equation 2 for the data
analysis, we believe that it is preferable to use an Equation
that yields reliable parameter values even though it has an
empirical element. Kinetic data that exhibit substrate inhibi-
tion were fitted using the combined Equations 3, 4, and 5 to
obtain best fit values and standard errors for ks, Vp, and V.
Where data showed no substrate inhibition, a reparameter-
ized version of the Michaelis-Menten Equation 6 was used for
the analysis to obtain best fit values and standard errors for
ks and Vm.
FIG. 1. Kinetics of wild-type SULT1A1 and SULT1A3 toward pNP and dopamine. Each data point () is an average of duplicate assays,
and the standard deviation is contained within the dimensions of the circle. a, activity of SULT1A1 with pNP as the substrate with the
concentrations up to 10 M. b, SULT1A1 with dopamine concentrations up to 5 mM. c, activity of SULT1A3 with dopamine as the substrate with
concentrations up to 100 M. d, pNP concentrations up to 6 mM. In a and c, the line represents the best fit to the data of Equation 3, whereas in
b and d, the line represents the best fit to the data of Equation 6.
Substrate Inhibition in SULT1A1 and -1A3 18801









v  ksS/1 ksS/Vm	 (Eq. 6)
To determine whether substrate inhibition involves the
three residues that interact with both pNP molecules (Ile-89,
Phe-247, and Val-148; Fig. 2a), in particular residue 247 as
suggested by the computer modeling, we employed site-di-
rected mutagenesis. Residues 247 and 148 were exchanged to
their counterpart residues in human SULT1A3 (F247L,
V148A), whereas residue 89 was converted to the smaller ala-
nine residue. His-108 was not mutated because it is reported to
function as a catalytic residue for sulfonation (31, 32) and is
found in all human sulfotransferases.
SULT1A1-F247L—When modeled into the SULT1A1 struc-
ture, the leucine in the mutant of phenylalanine at 247 to
leucine (F247L) does not form van der Waals interactions with
the nitro groups of pNP1 and pNP2, but there is no change to
the overall protein structure. Unlike wild-type human
SULT1A1 with dopamine, this mutant showed substrate inhi-
bition when dopamine was used as the acceptor molecule (Fig.
3a) and retained substrate inhibition with pNP (Fig. 3b). When
this mutant was analyzed kinetically, it showed an increased
affinity for pNP (Table I) and exhibited substrate inhibition at
a slightly lower pNP concentration.
Using Equation 3, we find that in the F247L mutant, there is
an increase of approximately 2-fold in the specificity constant
(ks) for both substrates, although neither the peak rate
(Equation 5) nor the limiting rate for SULT1A1-F247L is
significantly different when pNP is the acceptor molecule
(Table I). With dopamine as substrate, the peak rate is similar
to Vm when compared with the wild-type enzyme, with sub-
strate inhibition exhibiting a limiting rate of 78.9 nmol/min/mg
(Table I).
SULT1A1-V148A and SULT1A1-I89A—In the SULT1A1
crystal structure, the mutation of valine at 148 to alanine
(V148A) removes van der Waals interaction to the nitro group
of pNP1. The mutation of isoleucine at 89 to alanine (I89A)
disrupts the binding of pNP2 to the enzyme. These mutants did
not show any significant effect on substrate inhibition pattern
with dopamine or pNP (Table I).
FIG. 2. a, pNP interactions with the
SULT1A1 binding pocket as shown by the
crystal structure of SULT1A1. pNP1
shows van der Waals interactions (shown
by dotted lines) with Val-148 and Phe-247
and pNP2 shows interactions with Phe-
247 and Ile-89. The residues that are
present in the substrate binding pocket
but not shown for clarity are Ile-21, Phe-
24, Met-77, Pro-90, Ala-146, Tyr-169, Tyr-
240, and Val-243. b, SULT1A1 structure
with dopamine modeled into the sub-
strate-binding pocket. The alternate con-
formation of residue Phe-247, which al-
lows the binding of second dopamine
molecule (DP2), is shown in pink. The res-
idues not shown for clarity are Ile-21,
Phe-24, Met-77, Pro-90, Ala-146, Tyr-169,
Tyr-240, and Val-243. c, substrate-bind-
ing pocket of the modeled SULT1A3
structure. The binding mode of two do-
pamine molecules and PAPS is shown.
Residues not shown for clarity are Ile-21,
Phe-24, Pro-90, Tyr-240, Val-243, and
Met-248. The catalytically active dopam-
ine molecule 1 (DP1) is shown in orange
and dopamine 2 (DP2) in green. PAPS is
shown as a stick model.
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Substrate inhibition is a characteristic feature of many sul-
fotransferases, observed usually at high concentrations of their
preferred substrates. However, in general, the Michaelis-Men-
ten model has been used to explain catalysis by SULT1A1 and
SULT1A3 at moderate substrate concentrations (26, 33). In
previous work, we proposed a model that links the observed
substrate inhibition to the finding that there are two substrate
molecules bound near to the active site in the crystal structure
of SULT1A1 (21). One substrate molecule (pNP1) is in the
correct position for sulfonation, whereas the other (pNP2)
blocks the channel that leads to the active site. In this model,
inhibition results because the rate constant for catalysis is
higher when pNP2 is absent than when it is present. Thus,
there is impeded catalysis when both binding sites are occu-
pied, which we imagine is caused by molecular crowding that
perturbs the positioning of pNP1. In addition, when the pNP2
alone is bound, access to the active site is prevented. The
combination of these two effects results in the observed sub-
strate inhibition.
In our present study, the differing patterns of substrate
inhibition relating to the substrates (pNP and dopamine) of
SULT1A1 and SULT1A3 suggested to us that the substrate-
binding pocket of SULT1A1 may not accommodate two mole-
cules of dopamine or that binding of the second substrate
molecule may have been impeded in some way. To investigate
this, we modeled dopamine into the substrate-binding pocket of
the human SULT1A1 structure. We found that the substrate-
binding pocket of SULT1A1 could accommodate two molecules
of dopamine, although one enzyme residue (Phe-247) made
unfavorable interactions with the second molecule. This led us
to hypothesize that this residue may be important in substrate
inhibition. Site-directed mutagenesis of Phe-247 to the smaller
leucine residue found in SULT1A3 gave rise to substrate inhi-
bition in SULT1A1, suggesting that dopamine can be accom-
modated in the second binding site without making unfavor-
able interactions with the enzyme. Therefore, this residue
seems to be involved in the phenomenon of substrate inhibi-
tion, because mutations in other residues that interact with
pNP (Ile-89 and Val-148) exhibited kinetic profiles that are
similar to the wild-type SULT1A1.
The size and nature of the substrate binding pocket of
SULT1A1 and SULT1A3 suggest that much larger molecules
than pNP can be accommodated. Endogenous substrates such
as iodothyronines and 17-estradiol (E2) have shown to be
catalyzed by SULT1A1 with a clear substrate inhibition (34,
35). SULT1A3 also sulfonates the above substrates with a low
affinity (34, 36), and higher concentrations of these substrates
needed to be analyzed to investigate substrate inhibition. In
fact, 3,3-diiodothyronine (T2) was recently identified as the
endogenous substrate of SULT1A1 (37), and we identified a
catalytically feasible binding conformation when T2 modeled
into the active site of SULT1A1 (21). In this conformation, the
two phenyl rings of T2 occupy each of the pNP binding sites by
adopting a bent conformation. We also discussed in the same
article that a rigid multi-ring substrates such as E2 cannot
accommodate the binding pocket without a conformational
change in the enzyme. However, with both T2 and E2, it is
unlikely that two molecules will occupy the substrate binding
site of these two isozymes. Therefore, substrate inhibition
would probably occur by some other mechanism.
It is important to note that in the case of SULT1A1, Chen et
FIG. 3. Kinetics of the SULT1A1-F247L mutant toward p-nitrophenol and dopamine. Each data point () is an average of duplicate
assays, and the standard deviation is contained within the dimensions of the circle. a, activity of F247L mutant as a function of dopamine
concentration up to 5 mM; b, pNP to 3 M. The lines represent the best fit to the data of Equation 3.
TABLE I
Kinetics of SULT1A1 wild type and the F247L, V148A, and I89A mutants
The specificity constant (ks) is equivalent to Vm/Km in Michaelis-Menten kinetics, where Vm is the maximum velocity and Km is the Michaelis
constant. For cases in which substrate inhibition is observed, Vp is the rate at the peak, whereas rate V is the limiting rate S 3 .
Enzyme Substrate ks Vm Vp V
ml/min/mg nmol/min/mg nmol/min/mg nmol/min/mg
Wild type pNP 636  14 N.A.a 464  6 125  16
F247L pNP 1211  37 N.A. 308  4 123  9
V148A pNP 2210  52 N.A. 491  5 117  9
I89A pNP 2672  90 N.A. 746  11 158  16
Wild type Dopamine 0.302  0.021 187  4 N.A. N.A.
F247L Dopamine 0.638  0.033 N.A. 142  3 79  5
V148A Dopamine 0.425  0.023 64  0.9 N.A. N.A.
I89A Dopamine 1.154  0.128 219  6 N.A. N.A.
a N.A., not applicable.
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al. (38) have reported that residues Glu-83, Asp-134, Glu-246,
and Asp-263 are involved in the catalytic activity of SULT1A1
based on their SULT1A1 model. However, the crystal structure
of SULT1A1 suggests that the impaired activity seen with
mutations of these residues is caused by a perturbation of the
4 strand and 6 helix, potentially disrupting the structure of
the backbone. In a recent publication, the same authors (39)
used their SULT1A1 model (although the crystal structure of
SULT1A1 was published at the time) to demonstrate the im-
portance of arginine residues for SULT1A1 catalytic activity.
For example, they showed that when arginine at position 78
was mutated to a glutamic acid (R78E), SULT1A1 lost its
activity for 2-naphthol, whereas when it was mutated to ala-
nine (R78A), the enzyme retained activity. Based on their
SULT1A1 model, they suggested that the positive charge at
position 78 is not critical for activity. When it was mutated to
a negatively charged residue, there was a significant reduction
in activity, which they suggested was caused by an effect on
lysine 106 (Lys-106). However, the SULT1A1 crystal structure
shows that Lys-106 is 12 Å from Arg-78 and therefore unlikely
to be affected by the mutation. A more likely cause is a disrup-
tion of a hydrogen bond or charge-charge interaction network
involving Asp-59 and Gln-56. These two residues are located on
the 2 helix just preceding the phosphate sulfate binding loop,
which is critical for PAPS binding (14, 16, 20, 21). The crystal
structure suggests that the R78E mutant would probably dis-
rupt this network, thereby destabilizing PAPS binding because
of unfavorable charge-charge interactions.
The crystal structure of the major catecholamine sulfotrans-
ferase, SULT1A3, was the first three-dimensional structure of
a human cytosolic sulfotransferase to be solved. This structure
was published simultaneously by both our group (15) and
Coughtrie and co-workers (16). The Bidwell et al. (15) structure
was solved with a sulfate ion bound at the active site, whereas
the Dajani et al. (16) structure was complexed with the product
3-phosphoadenosine 5-phosphate. Significantly, both groups
reported that about 25% of the SULT1A3 structure consisted of
disordered regions, probably because of the lack of a bound
substrate. Most of the 68 disordered residues in the
apoSULT1A3 structure correspond to the substrate-binding
regions in SULT1A1 (21).
When examining the model of SULT1A3, it highlighted the
importance of residue 247 (leucine in SULT1A3 and phenylala-
nine in SULT1A1) in accommodating two dopamine molecules
in the substrate binding site. These modeling data convincingly
demonstrate that the observed substrate inhibition in
SULT1A3 with dopamine is caused by impeded catalysis when
two molecules of dopamine are present in the active site. The
molecular mechanism of this substrate inhibition can be ex-
plained by using the proposed kinetic model for SULT1A1 (21).
In contrast to SULT1A1, the modeled SULT1A3 substrate-
binding pocket has more charged residues, such as aspartate
and glutamate (Fig. 2c), and these would favor binding of
substrates having positively charged groups, such as dopam-
ine. The model not only highlighted the importance of residue
247 but also showed the importance of three other residues:
Asp-86, Glu-89 and Glu-146 for substrate interaction. With the
aid of molecular modeling (based on the mouse SULT1E1 struc-
ture) and site-directed mutagenesis, we and others have previ-
ously identified these three residues as responsible for the high
dopamine affinity of SULT1A3 (26, 40–42). In our SULT1A3
model, Glu-146 is placed within hydrogen-bonding distance of
the amino group of the first dopamine molecule (Fig. 2c). The
importance of this interaction in dopamine sulfonation is con-
firmed by the functional studies of Brix et al. (41). They have
shown that by changing Glu-146 in SULT1A3 to glutamine
(abolishing the negative charge), there is a 360-fold decrease in
the specificity constant for dopamine. Furthermore, the change
of a single amino acid, E146A, in SULT1A3 was sufficient to
change the catalytic properties and substrate specificity so that
it mimicked those of SULT1A1 (40, 41, 43). A related study
from our laboratory showed that the mutant A146E in
SULT1A1 yielded a SULT1A3-like protein with respect to pNP
(41). Taken together, these data provide strong evidence that
residue 146 is crucial for recognition of dopamine and deter-
mining the substrate specificity in SULT1A1 and SULT1A3.
Mn2 has shown to stimulate dopamine sulfonation by
SULT1A3, and this is proposed to occur via interaction between
Mn2 and Asp-86 which is in the mobile loop having residues
86–90 (44, 45). Further, at higher concentration of Mn2, it
appeared that there was no substrate inhibition observed for
dopamine. We can therefore use our model to propose how this
takes place if substrate inhibition no longer occurs in the pres-
ence of Mn2. This would imply that the second dopamine
molecule would be displaced by Mn2 binding. We investigated
the region of Asp-86 and found that the amine of second do-
pamine molecule interacts with Glu-89, which is only 4–6 Å
from Asp-86 (Fig. 2c). Glu-89 represents the only non-hydro-
phobic interaction for the second dopamine molecule. We there-
fore propose that Mn2 binding at the SULT1A3 binding site
may involve both Asp-86 and Glu-89 side chains. This interac-
tion would prevent binding of the second dopamine molecule by
removing a major protein interaction. This is further supported
by the fact that Glu-89 is replaced by isoleucine in SULT1A1,
this protein shows very low substrate binding affinity for do-
pamine, and its activity is unaffected by adding Mn2 (44, 45).
The mutation of Glu-89 in SULT1A3 to isoleucine results in
reduced activity toward dopamine (42, 45). In the SULT1A3
crystal structure (15), residues 86–90 form a mobile loop that
intercalates into the active site of a symmetry-related mono-
mer. The residues in this region are poorly ordered and were
suggested to have the potential to undergo disorder-order tran-
sition upon substrate binding. In our model of SULT1A3, this
flexible loop tucks back in to the same subunit to close over the
active site, as in the crystal structure of SULT1A1, and Glu-89
is placed within hydrogen-bond distance to the second dopa-
mine molecule. Even though the mechanism for low activity
remains unclear, this mutant may have altered structural in-
teractions of the flexible loop with the substrate. Then again,
the decreased overall charge of the substrate-binding pocket
may make it less able to bind dopamine.
The data from these investigations support the reliability of
our SULT1A3 model, as well as the previously proposed hy-
pothesis that inhibition in SULT1A1 and SULT1A3 is caused
by binding of a second substrate molecule at the substrate
binding site, and suggest a major role for residue 247 in sub-
strate inhibition of human SULT1A1.
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